Mirati Therapeutics Gross Profit

The latest gross profit for MRTX is $34M as of September 2023. That compares with $12M in the prior-year period — up 188.6% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside Mirati Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MRTX's gross profit moved from $12M to $34M — a 188.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mirati Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, MRTX currently prints $34M for gross profit, while the sector average sits near $66B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at Mirati Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $34M for MRTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting MRTX's gross profit ($34M), review year-over-year change from $12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.